AASLD 2022

News


Dr. Mindie Nguyen, President of the International Association for the Study of the Liver (IASL) served as co-chair of the Advanced Research Training Course in collaboration with Beijing Youan Hospital in Beijing, China on December 7, 2024.  The intensive program provided young physicians with the opportunity to develop essential skills in research development, analysis, and publication, guided by international faculty members from the United States, Canada and China, including Dr. Ramsey Cheung from Stanford University.

The IASL, a nonprofit organization, is dedicated to advancing hepatology globally by promoting education, fostering research, and supporting international collaboration on liver and biliary diseases. Through programs like this course, IASL aims to train experts and advance knowledge to improve liver health worldwide.


Sex Differences in Adverse Liver and Nonliver Outcomes in Steatotic Liver Disease

New Nguyen Lab Study by Dr. Taotao Yan, MD, PhD and colleagues as published in the Decembr 4,  2024 issue of Journal of the American Medical Association Network Open indicates Serious MASLD Outcomes Affect Men and Women Differently.

Presentation at Taiwan Digestive Disease Week 2024, Awarded 2nd Prize for Research Award

Joanne Liu presented a study on projecting the changes in tumor characteristics and survival of patients with nonviral hepatocellular carcinoma (HCC) in the United States, using the Surveillance, Epidemiology, and End Results Program (SEER)-Medicare database. Though the early-stage detection and survival of nonviral HCC is improving, our projections estimate that a third of patients will be diagnosed with TNM stage III or IV tumors by 2027, 5-year survival rates will remain <25% by 2027, and median survival will remain <1.5 years by 2035. These findings suggest that more effort is needed to improve surveillance and therapeutic strategies for nonviral HCC. 

Targeted outreach to eliminate the disease by 2030 is required, experts say in the Journal of Hepatology

New evidence reveals global underassessment and undertreatment of chronic hepatitis B (HBV), especially among women and Asian minorities in the West, a new study(opens in new tab/window) in the Journal of Hepatology(opens in new tab/window), published by Elsevier, details.

 

Hepatitis Treatments Underutilized Among ‘Sickest’ With Liver Cancer

January 19, 2024
Alex Briese

Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even among patients who undergo curative surgery.


Global burden of hepatitis B virus: current status, missed opportunities and a call for action

Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also include acute flares and extrahepatic manifestations. In addition, people living with HBV infection also experience stigma. read more

Treatment for hepatitis C remains low, despite success

December 13, 2022 - By Emily Moskal

Antiviral treatment reduces complications of hepatitis C infection, but only two out of every three patients diagnosed with the virus receive the treatment, according to two recent studies led by Mindie Nguyen, MD, professor of gastroenterology and hepatology.

“I’m hoping the data will bring home the magnitude of the problems,” said Nguyen, the senior author of both papers. “The benefits are clearly shown in our study. We are looking at a population with probably better coverage than anyone — patients in the United States with private insurance — yet less than 65% of people diagnosed with hepatitis C received treatment. That is quite sobering.”

DAAs with, without PIs yield similar outcomes in decompensated HCV cirrhosis

AN DIEGO — Researchers reported similar clinical outcomes in patients with decompensated hepatitis C virus cirrhosis treated with direct-acting antivirals, with or without protease inhibitors, according to study results. See More

PI-based DAAs appear safe in decompensated patients

AT DDW 2022

SAN DIEGO – An analysis of a large, international cohort suggests that treatment with protease-inhibitor (PI)–based direct-acting antivirals (DAAs) may be safe for patients with hepatitis C virus (HCV) with cirrhosis and early-stage liver decompensation. See More

 

Using data from a US population-based epidemiology survey, the authors of this article found that people born after 1991 had better hepatitis B vaccination effectiveness and vaccinated individuals had lower all-cause and cancer-related mortality. see more

Therapy Slices HCC Risk in HBV's Indeterminate Phase 

AASLD-The Liver Meeting, November 4-8, 2022, Washington, DC
Mark Mascolini
Antiviral therapy for chronic hepatitis B virus (HBV) infection in the indeterminate phase sliced HCC risk by 70% through 15 years of follow-up [1]. Researchers from the National University of Singapore and REAL-B Consortium colleagues across the world believe their findings may support expansion of chronic HBV treatment criteria. see more